Week 142 Review - Optibiotix recovery begins

An absolutely brilliant week with one of my biggest gains so far. It's nearly all thanks to OPTI:Optibiotix which has started to climb after a period of really bad performance. Good job I bought some more last week then! The deficit reduced by £5,000 exactly this week, which is a massive relief after last week's disaster. The deficit now stands at £6,043 but portfolio value is up to £73,219.

There were still loads of shares in the red this week, with small drops being hidden by the big rise in OPTI:Optibiotix.

CAML:Central Asia Metals had an utterly disastrous week. I expected a dip on ex-dividend day, but there was selling into the dividend as people took the profits from the gains prior to the drop on ex-date, but then more people sold just after they qualified for the dividend, which was a mistake as the price had fallen so much more than the dividend is worth. My holding fell by 19% of the original purchase price, so a share that I recently had to top-slice to get down to 10% of my portfolio is only making up 7.9% of it. Last time it dropped to this level was early February, but it reached a new high a month later, so I'm confident when things settle down this will be back up around 340p.

LION:Lionsgold was rubbish again this week and dropped 11%. The less said about this massive mistake the better!

VRS:Versarien had a really good week and climbed 7%, putting it back into profit albeit only £39. Hopefully the recent blip is out of the way and this can slowly but steadily climb from here. That's never going to happen though. This one's going to be manipulated and traded for a long time yet.

SBTX:SkinBioTherapeutics followed on from last week's amazing performance with another 7% rise, and is only 12% down on my purchase price 20 seconds after the IPO launch. Looking at the number of shares held by OPTI:Optibiotix, there's an outside chance I could get up tp 30,000 of these if they offer one share for each two OPTI:Optibiotix shares. That would be nice!

Share of the Week OPTI:Optibiotix climbed 9p this week which was around 14%. With my enlarged holding, 9p is worth £5,697 so it would have been a negative week without this contribution. My holding is now making a loss of £768 so no longer Nemesis Share. There's a big question mark over whether this rise will hold though. Look at the chart and you can see we've been here before, but the traders start selling as soon as there's a spike. Without firm revenue predictions to bring in the institutions, this will carry on and we'll be back at 56p before long. One day it will stop, and that day is coming closer!

Nice tick up almost halving the deficit

Here's the ISA and share accounts performance

			Weekly Change
Cash	£10.86		+£0
Portfolio cost	£51,874.49		+£0
Portfolio sell value (bid price - commission)	£45,126.95	(-13%)	+£3,594.21
Potential profits	£260.12		-£74.44
Yr 3 Dividends	£44.15		+£0
Yr 3 Profit from sales	£8,033.77		+£0
Yr 3 Average monthly cash profit	£917.75	(21.2%)	-£24.80
Total Dividends	£1,223.20		+£0
Total Profit from sales	£14,746.27		+£0
Average monthly cash profit	£483.20	(11.2%)	-£3.43
(Sold stocks profit + Dividends - Fees / Months)

Potential profits are actually down thanks to the 4% drop in MTFB:Motif Bio. However sell value is massively up thanks to OPTI:Optibiotix. Average monthly profit will tick down at 0.1% a week now so I have at least 12 weeks buffer before I go back below my 10% target. This might accelerate if the portfolio value goes up - I should hope!

Still a long way to go, but nice to see it heading in the right direction.

The SIPP looks like this after week 126

			Weekly Change
Cash	£19.97		+£0
Portfolio cost	£27,016.24		+£0
Portfolio sell value (bid price - commission)	£27,897.06	(3.3%)	+£1,442.87
Potential profits	£2,765.78		-£721.46
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£1,023.84		+£0
Yr 3 Average monthly cash profit	£191.53	(8.5%)	-£9.12
Total Dividends	£916.10		+£0
Total Profit from sales	£9,949.03		+£0
Average monthly cash profit	£366.82	(16.3%)	-£2.93
(Sold stocks profit + Dividends - Fees / Months)

Potential profits were crippled thanks to a dreadful week for CAML:Central Asia Metals and a drop for LGEN:Legal & General following dividend ex-date. No matter, as they will both bounce back quickly, and OPTI:Optibiotix climbed enough to offset that and still finish up £1,442 better off. At the current rate of decline for the average monthly profit, I won't need to sell a share for 63 weeks and still be above my 10% target. I somewhat doubt that's going to happen though!

Back in the black!

The trading account was looking more optimistic after week 91. That's not the case after week 92!

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£269.13	(-51.1%)	-£37.67
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£23.67	(-82.2%)	+£0.61
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£11.31	(-39.3%)	+£0.13
(Sold stocks profit + Dividends - Fees / Months)

 Back down to a 50% loss and unlikely to be going anywhere upwards soon. The only slight ray of hope is that if i had been watching this share in anticipation of a pump, I probably would be buying around now, but selling at the price I originally bought them - doh!

Hopeless.

Next week will reveal whether OPTI:Optibiotix can continue the upward momentum and get into profit, or whether we'll return to the cycle of traders selling out and forcing down the price. If the traders are circling then I only hope this time they let the price rise a bit more before they start. I'd much rather be trapped in a 70p-80p range than a 50p-60p range, as all I can think of is how many people are arriving late on the scene and buying in cheaper then me! Does that make be a bad person?

I'm expecting CAML:Central Asia Metals and LGEN:Legal & General to recover from their blip so the SIPP should have a good week next week. KIBO:Kibo Mining must surely be near the signing of their Power Purchase Agreement which could see an epic rise back into profit. I don't think any other news is expected, so maybe we'll have a nice quiet week...

Week 141 Review - Practically no paper profit left

The key event this week was selling the remainder of my ISA holding in IQE:IQE which had a devastating impact on my paper profits, and exposed that fact that one share had been propping up my paper performance for a long time. The sale combined with a dreadful week saw the gap between cost and value of the combined portfolios drop by £4,411 to £11,043 and a portfolio value back below £70K at £68,193.

Biggest drop was N4P:N4 Pharma which fell a massive 17% despite news that trials of their Viagra replacement Sildenafil are about to begin. They were in profit last week but now down 12% which is rather frustrating.

IQE:IQE fell by 13% as the shorters take control. Maybe I should have kept the cash from the shares I sold to buy back once they get clobbered. Instead I'll have to watch my remaining SIPP holding plunge to a big loss like the rest of my shares.

OPTI:Optibiotix released yet more good news but the effect was the same as usual as it fell 5%. That's 3p and so contributed to £1,900 of this week's loss.

My favourite yo-yo share CAML:Central Asia Metals had a down week this week, falling 6%. I thought there would be a rise as people buy in for the dividend, but no.

Although the general sentiment was gloomy this week, there were a few good news stories. MTFB:Motif Bio are gradually sneaking up now the NDA is being incrementally submitted. They rose 6% this week and are now 10% up, which gives me paper profit of £316 with my enlarged holding.

A holding RNS revealed Woodford has increased holdings by 1% in TRX:Tissue Regenix which explains the recent recovery. Up 7% this week but still 48% down on purchase price.

Share of the Week is SBTX:SkinBioTherapeutics which zoomed up 15%. Is there danger this could finally get back into profit before my free shares arrive? They are only 19% down on purchase price now.

The recovery didn't last very long, and the gap is now wider than ever.

Here's the ISA and share accounts performance

			Weekly Change
Cash	£10.86		+£4.25
Portfolio cost	£51,874.49		+£1,764.84
Portfolio sell value (bid price - commission)	£41.532.74	(-19.9%)	-£3,093.26
Potential profits	£334.56		-£1,836.59
Yr 3 Dividends	£44.15		+£0
Yr 3 Profit from sales	£8,033.77		+£1,786.99
Yr 3 Average monthly cash profit	£942.55	(21.8%)	+£188.92
Total Dividends	£1,223.20		+£0
Total Profit from sales	£14,746.27		+£1,786.99
Average monthly cash profit	£486.63	(11.3%)	+£51.84
(Sold stocks profit + Dividends - Fees / Months)

Cost increased as the IQE:IQE profits were re-invested and accounted for nearly all the drop in potential profits. The rest of the portfolio lost around £1,200 much of which was OPTI:Optibiotix. The effect of the sale on average monthly profit was amazing, passing 11% and giving me plenty of time above my 10% target before having to make another sale.

As with the combined chart, this looks dreadful

Here's the SIPP after week 125

			Weekly Change
Cash	£19.97		+£0
Portfolio cost	£27,016.24		+£0
Portfolio sell value (bid price - commission)	£26,454.19	(-2.1%)	-£1,314.64
Potential profits	£3,487.24		-£257.00
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£1,023.84		+£0
Yr 3 Average monthly cash profit	£200.65	(8.9%)	-£10.03
Total Dividends	£916.10		+£0
Total Profit from sales	£9,949.03		+£0
Average monthly cash profit	£369.75	(16.4%)	-£2.98
(Sold stocks profit + Dividends - Fees / Months)

General misery as unlike last week when everything went up, this week everything except TRX:Tissue Regenix was down.

Back in the red after a fleeting week in the black.

Here's the trading account after week 91

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£206.08	(-40.2%)	-£2.98
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£24.28	(-84.3%)	+£0.64
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£11.44	(-39.7%)	+£0.13
(Sold stocks profit + Dividends - Fees / Months)

Hardly any change in LION:Lionsgold this week, and possible news of the Railsbank takeover next week.

There's still hope!

Although it's been a miserable week, it could have been worse. I was looking at IMM:Immupharma at the same time I was looking at N4P:N4 Pharma but gave them a miss as it seemed a shit or bust strategy compared to N4P:N4 Pharma with a more diverse portfolio. Unfortunately for shareholders it was a bust, as the share price collapsed following disappointing trial results. At least this week's losses were relatively small for my portfolio and could bounce back quite quickly.

I've used up all my ammo selling IQE:IQE so have no more wiggle room for other purchases. I'm really happy with the shares I bought using my IQE:IQE profits, but have to accept they are all pre-revenue and high risk. All I can do now is sit back and wait, and hope I made the right decisions.

ISA IQE holding sold - More Versarien bought, and had to get more Optibiotix

I cracked at lunchtime and sold the rest of my ISA holding in IQE:IQE.

The shorters aren't giving up, and with no prospect of news in the near future I've been toying for a while with cashing in all my big profits and just keeping my loss-making SIPP shares.

I think IQE:IQE probably have a bright future, and I really, really hope that's the case, and so want to keep a decent number of shares so I can benefit from that, and if the opportunity arises buy more.

There's just one nagging doubt, and that's the amount of time it's taking to get five new machines up and running to meet escalating demand. For the next 12 months, the cost of scaling up production looks like it will be huge, so the ability to generate cash is severely limited.

I'm starting to think that's why the shorters are still in control, and will be for some time.

I sold my remaining 3,035 shares at 118.1p and made £1,786.99 (99.4%) profit, liberating £3,575.39.

IQE:IQE has been by far my most profitable share. In fact, without it my performance would be rubbish. I've made £11,981.81 (128.6%) profit which is absolutely stunning, and whatever happens to the IQE:IQE share price from now, I'm happy with that.

I still have 1,809 shares in the SIPP but I paid 131.45p for those, so they are down by 11%, but I'll lock those away for the long term now.

The sale has made a dramatic improvement in my average monthly performance, lifting it to £490 per month over 2.5 years, which is 11.3% of the (recently enlarged) portfolio cost.

So why did I sell now?

It's because my two favourite shares of the moment have become so stupidly cheap that I couldn't resist buying more.

I want to get VRS:Versarien up around 10% of my portfolio value so I can top-slice to keep it at 10% as it climbs. I like that model and it works really well with CAML:Central Asia Metals, and the VRS:Versarien price has slipped just recently. It appears to be Miton selling their shares in order to meet redemption requirements. This has to be complete by the end of April, but given the cash has to clear before they can dish it out, I think they must be nearing the end of their selling spree.

My average purchase price is 75.12p and they closed yesterday with an offer price of 65p, so a full 10p cheaper then the ones I bought. With that in mind I bought 3,063 at 65p costing £1,999.90. By the end of the day the offer price had risen to 68p and bid price 65p, so the spread has been eliminated today.

This increased my holding to 7,626 shares costing £5,439.58 and a weighted average price of 71p.

Tragically they are down by 13% and losing £723 but when they bounce it should be good. Each 1p rise is worth £76, and when they shift they really tend to shift.

My other purchase was naughty, but I can't stand by and see another fantastic OPTI:Optibiotix RNS for a good revenue-generating contract result in yet another drop in share price. It's just too depressing! I was planning to sink all my IQE:IQE profits into VRS:Versarien but I absolutely had to get some more OPTI:Optiobiotix at this price.

My weighted average in the ISA was 66.9p but I bought 2,639 shares at 59.2p (crazy madness!) costing £1,571.24. This dragged my weighted average down to 66.3p. Hoped it would be a bit more than that! As usual, had I waited I could have bought them for 58p by the end of the day.

That takes my total holding to 63,361 shares and each 1p change in price is now worth £633. They are losing £5,837 at the moment, but I am so utterly convinced that these are going to be profitable this year, that I really don't care.

Needless to say the sale of IQE:IQE had a devastating impact on my portfolio paper profits which are down £3,704 this week and the gap between cost and value has a deficit of £10,336 with almost every share losing money. Only three shares are actually in profit, but that's what comes from investing in volatile startup companies that go through a significant period of doubt before the shares either plummet or soar. I only need one or two to soar (as long as one of them is OPTI:Optibiotix) for this strategy to pay out.

If OPTI:Optibiotix lets me down then the whole thing comes crashing down around me, but that's a risk I'm willing to take after following this story for 2.5 years as all the pieces of the jigsaw are meticulously put in place ready to create a stunning picture.

Week 140 Review - Lots of small rises continue the recovery

A week when there were small rises throughout the portfolio. Slightly dented by a few big drops, but generally a strong week. The deficit improved by £1,386 and now stands at £6,631 with a total combined portfolio value of £70,866 back above the magic £70K.

Worst performer was KIBO:Kibo Mining which tanked 10% after announcement of a placing. Very frustrating that more money is being raised to fund a new project when the original one isn't secure yet. Just when I thought this was turning round, some doubt is sown in my mind about the motives of the directors. I'm now 25% down on this one, and with £2,635 invested it's 3.4% of my portfolio. I'm not miffed enough to sell with that loss, so will hang on in there hoping for a PPA and reasonable re-rate.

WRES:W Resources did the usual trick of noticing a rise in the share price and so announcing yet another placing, despite £35m of debt funding a great big grant from the Spanish Government. I really am keen to sell these things once they get into profit as I don't trust the CEO as far as I can throw him, and I have a bad back! They dropped 6% this week, probably as a result of the placing.

MTFB:Motif Bio was Share of the Week last week, so not too surprising there was some profit taking this week and a 5% drop. Fortunately not enough of a drop to wipe out my paper profits which are £120 (4%).

My other recent topped-up newcomer is VRS:Versarien, and that also fell 5% but is now 6% down so I bought at the wrong time again. The mistake was topping up when I got excited about prospects. I should have realised there would be a better price to do so. This is a very news dependent share so could drift for a while without any.

On to the good news shares, with OPTI:Optibiotix climbing 2p and contributing a major part of the good performance. This was despite no real news, so when that RNS finally lands, who knows what will happen?!

LGEN:Legal & General don't usually move very much, but a 5% increase this week was most welcome and puts them £544 (35%) up in my SIPP. The ex-dividend date is Thursday after next, and with an 11.05p dividend they will tank that day, but the £87 payout next month will be nice.

CAML:Central Asia Metals had a great set of results and announced a 10p final dividend worth £205 so my SIPP has some nice treats coming. Share price was up 6% at the end of the week so these are now 88% up on my purchase price making potential profit of £3,143 and having generated £647 dividends and £982 realised profit from sales. What a great company!

TRX:Tissue Regenix has mysteriously climbed 9% on no news whatsoever. I'm not sure what's driving that up, but clearly there is some serious buying going on. I'm still 55% down so there's a long way to go, but maybe a glimmer of hope.

IQE:IQE are sneaking back up very slowly. They gained 4% in my SIPP and are now only 5% underwater, whereas my ISA holding climbed 10% of purchase price and are 114% up. Hopefully they can stabilise around 140p for a while, but these have been anything but stable.

LION:Lionsgold nearly won Share of the Week after a big climb today making them 15% up for the week. They announced having made an offer to buy out 100% of TRAC (The Real Asset Company) and therefore Goldbloc, which in theory will be a crypto-currency based on buying physical gold. It may or may not take off, but is incredibly volatile so I'm hoping this will be the news that gets it to the 6p region so I can sell and start using my trading account properly.

Share of the Week is TND:Tandem Group, which climbed 15% following really strong results. I do regret buying these early on in my investment days, as it's horribly illiquid with a huge spread, which puts so many people off buying them. They are still 30% down after years and the £42 dividends are not enough to make up for that. It is almost tempting to salvage £758 and take a £325 loss just so I can do something more useful with the cash, but their p/e ratio is only 9 so I'm loathe to sell when they could so easily rise by 50% from here on relatively few purchases.

Pointing in the right direction, but a long way to go yet.

The ISA and share accounts look like this

			Weekly Change
Cash	£6.61		-£3.75
Portfolio cost	£50,109.65		+£0
Portfolio sell value (bid price - commission)	£42.861.16	(-14.5%)	+£303.73
Potential profits	£2,171.15		-£13.85
Yr 3 Dividends	£44.15		+£0
Yr 3 Profit from sales	£6,246.78		+£0
Yr 3 Average monthly cash profit	£753.63	(18.0%)	-£22.00
Total Dividends	£1,223.20		+£0
Total Profit from sales	£12,959.28		+£0
Average monthly cash profit	£434.79	(10.4%)	-£3.25
(Sold stocks profit + Dividends - Fees / Months)

Most of this week's losses were in the ISA, so potential profits are actually slightly down on the MTFB:Motif Bio drop. Rises in IQE:IQE weren't enough to offset that. Overall a small rise of £303 so it may take a while to plug the £7,000 hole.

The gap is still very wide and the rise very shallow

The SIPP looks like this after week 124

			Weekly Change
Cash	£19.97		-£10.13
Portfolio cost	£27,016.24		+£0
Portfolio sell value (bid price - commission)	£27,768.83	(2.8%)	+£1,023.99
Potential profits	£3,744.24		+£273.17
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£1,023.84		+£0
Yr 3 Average monthly cash profit	£210.68	(9.4%)	-£13.40
Total Dividends	£916.10		+£0
Total Profit from sales	£9,949.03		+£0
Average monthly cash profit	£372.73	(16.6%)	-£3.39
(Sold stocks profit + Dividends - Fees / Months)

The reduction in cash was due to monthly charges, but everything else very positive. Everything was up except ARL:Atlantis Resources which is still suspended and has been for four months today. The other faller was N4P:N4 Pharma which is highly volatile, but fortunately still 5% up on purchase price. Everything else was up.

Back into the black!

Here;s the trading portfolio after week 90

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£209.78	(-39.3%)	+£59.13
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£24.92	(-86.5%)	+£0.67
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£11.57	(-40.2%)	+£0.13
(Sold stocks profit + Dividends - Fees / Months)

At last some movement upwards in LION:Lionsgold. Next week will either see a spike so I can sell or a re-trace as traders take their profits before I do. Seeing as this portfolio is cursed, I suspect the latter!

Woohoo!

I had some troubling news this week. It had been six months since I put plans in motion to transfer my pension fund, which is about the maximum I should have been expected to wait, so I contacted my Financial Advisor who seemed shocked. He had requested a new transfer quote on my behalf as the last one had expired, but I didn't know this and it never arrived. He thought I'd decided not to proceed! Given I've not had a pay rise this year and the valuation is based on salary, I've effectively lost 6 months of potential interest. Not happy!

It's going to be warm and sunny next week, so I can be easily distracted from peering at my portfolio - the garden beckons...

Week 139 Review - A blue week at last!

At last the rot has stopped and we have a blue week. Lots of small increases plus a 2p improvement in OPTI:Optibiotix resulted in an improvement between cost and value of £1,362. The deficit is still horribly large at £8,018 and the combined portfolio is still stuck below £70K at £69,493.

Worst performer was KIBO:Kibo Mining after a recent rally. These dropped 8%, probably as a result of the PPA not being quite as imminent as everyone expected. However, announcement of a second power generation project should be of long term value.

IQE:IQE dropped 6% in my SIPP and 13% in my ISA so the promised rally caused by closing shorts hasn't happened, even though the shorters are managing to close their positions. Very frustrating!

TLOU:Tlou Energy can't seem to revive after the re-tendering announcement. I thought it had fallen too far at 10p, but this week it dropped another 5% to 8p. At some point soon I'm sure there will be a rebound.

I thought I had purchased VRS:Versarien at just the right time, but I was wrong. A 4% slip this week took them from profit to loss. I never seem to find the bottom when I'm buying.

Thankfully a 2p rise in OPTI:Optibiotix gave me a £1,200 boost, and some 5% rises in RDT:Rosslyn Data and TND:Tandem Group also helped.

SBTX:SkinBioTherapeutics had a great week, climbing 7% but still 37% down, and recent purchase N4P:N4 Pharma also climbed 7% to go 7% into profit.

JLP:Jubilee Metals has had a miserable time lately, but announcement that the Kabwe licence has been re-instated was enough to move the share price up 9%, although a long way to go before being back above water.

Share of the Week is MTFB:Motif Bio which announced the beginning of a staged submission of its NDA this week, along with waiver of the $2m fee. That saw the shares recover by 12% and go back into profit.

It's a very tiny upward-pointing line, but at least it is pointing upwards.

Here's the ISA and share accounts

			Weekly Change
Cash	£10.36		+£0
Portfolio cost	£50,109.65		+£0
Portfolio sell value (bid price - commission)	£42.557.43	(-15.1%)	+£1,004.11
Potential profits	£2,185.00		-£25.12
Yr 3 Dividends	£44.15		+£0
Yr 3 Profit from sales	£6,246.78		+£0
Yr 3 Average monthly cash profit	£795.63	(18.6%)	-£22.81
Total Dividends	£1,223.20		+£0
Total Profit from sales	£12,959.28		+£0
Average monthly cash profit	£438.04	(10.5%)	-£3.17
(Sold stocks profit + Dividends - Fees / Months)

Potential profits were down slightly thanks to IQE:IQE but £1,004 improvement in value from reduced losses. Not much change elsewhere.

Very tiny tick upwards.

The SIPP looks like this after week 123

			Weekly Change
Cash	£30.10		+£0
Portfolio cost	£27,016.24		+£0
Portfolio sell value (bid price - commission)	£26,744.84	(-1.0%)	+£369.02
Potential profits	£3,471.07		+£68.78
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£1,023.84		+£0
Yr 3 Average monthly cash profit	£224.08	(10.0%)	-£12.45
Total Dividends	£916.10		+£0
Total Profit from sales	£9,949.03		+£0
Average monthly cash profit	£376.12	(16.7%)	-£3.08
(Sold stocks profit + Dividends - Fees / Months)

The £68 increase in profits is all thanks to N4P:N4 Pharma, as IQE:IQE and CAML:Central Asia Metals both had small losses this week.

Not quite back in the black.

The trading account looks like this after week 89

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£150.65	(-56.4%)	-£11.09
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£25.59	(-88.8%)	+£0.71
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£11.70	(-40.6%)	+£0.13
(Sold stocks profit + Dividends - Fees / Months)

Oh dear. The yo-yo effect has stopped, and it's heading down.

My optimism was short lived. I fear this portfolio may be doomed!

Next week has one key event - the CAML:Central Asia Metals results. How much will the new purchase have added to profits and what will the dividend be? There may be a price rise leading up to the results, but that risks a big drop on the day. I think I'd rather it stayed at this price and then has a little spurt on the day.

No plans to sell or buy anything for a while now, so it's a waiting game.

Week 138 Review - It keeps getting worse

Yet another bad week, with the difference between cost and value increasing by £1,344 as the total portfolio value fell to £68,131. The total deficit is now £9,380 which is the most it has ever been. This has partly been caused by banking a load of profit, but is mostly due to only 4 of my 24 holdings being in profit. That's pretty bad!

IKA:Ilika was the worst performer, dropping 6% after a recent mini rally. These were only a £500 punt so the fact they are 67% down isn't costing me much, and there is still hope of a turnaround if only they could get someone with half a commercial brain on the board.

RED:RedT Energy continue to slip, down another 5% along with TND:Tandem Group whose post-results markup has now been lost completely. These are trading on a p/e ratio of 6.8 which is crazy despite difficulties in the retail sector.

OPTI:Optibiotix fell 4% but that 3p drop cost £1,800 so this would have been a blue week if they had stayed still. I'm now losing £6,993 on these, so the current woes are in no small part down to the performance of this one share. Not surprising considering they make up 52% of my portfolio cost, even after recent re-investment substantially increasing total portfolio cost to £77,471. It's OK though - once they move upwards they will move fast, and that will come when there's some inkling of revenues.

Very few positive performers this week. KIBO:Kibo Mining is doing very well as news of the PPA comes closer. That ought to see a significant re-rate. This climbed 7% and is now only 7% down on my weighted average purchase. With 38,000 shares this could rapidly move into healthy profit, and there may be some free KAT:Katoro Mining shares due. However, with the recent announcement that the KAT:Katoro Mining gold project is unlikely to be economically viable, I'm rather glad I didn't invest independently of the potential free handout.

Share of the Week is N4P:N4 Pharma which climbed 10% and is only 93p in the red, so spread and commission are almost covered, and the momentum seems to be up after the initial dip. Hopefully I almost bought at the bottom of the dip, which would be much better than my usual performance.

The widest gap there has ever been between the lines.

The ISA and share accounts look like this

			Weekly Change
Cash	£10.36		+£0
Portfolio cost	£50,109.65		+£0
Portfolio sell value (bid price - commission)	£41.553.32	(-17.1%)	-£740.20
Potential profits	£2,210.12		+£106.33
Yr 3 Dividends	£44.15		+£0
Yr 3 Profit from sales	£6,246.78		+£0
Yr 3 Average monthly cash profit	£798.44	(19.1%)	-£24.19
Total Dividends	£1,223.20		+£0
Total Profit from sales	£12,959.28		+£0
Average monthly cash profit	£441.21	(10.6%)	-£3.22
(Sold stocks profit + Dividends - Fees / Months)

Potential profits were actually up this week, with small increases in my only profitable shares IQE:IQE and VRS:Versarien. IQE:IQE now comprises only 8% of my portfolio cost and 9.1% of my portfolio value, both well under the 10% maximum but on a slightly depressed share price so I have no ambition to add more. VRS:Versarien only make up 4.6% of portfolio cost and 5.2% of portfolio value, so I'm looking to double my holding to get to 10% as I really like the prospects - it's the nearest thing I have to OPTI:Optibiotix for global potential as leaders in a rapidly growing market.

Average monthly profits of 10.6% of my higher portfolio cost is comfortably above target, so despite the dip in paper performance, I'm above target for real income and have been able to build positions in some really exciting new companies.

Pretty bad, but not the worst it's been lately and hopefully ripe for a bounce.

The SIPP looks like this after week 122

			Weekly Change
Cash	£30.10		+£0
Portfolio cost	£27,016.24		+£0
Portfolio sell value (bid price - commission)	£26,375.82	(-2.4%)	-£589.47
Potential profits	£3,402.29		+£18.88
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£1,023.84		+£0
Yr 3 Average monthly cash profit	£236.53	(10.5%)	-£13.91
Total Dividends	£916.10		+£0
Total Profit from sales	£9,949.03		+£0
Average monthly cash profit	£379.20	(16.8%)	-£3.14
(Sold stocks profit + Dividends - Fees / Months)

Potential profits were just about up in here too, with LGEN:Legal & General making a small recovery tempered by a very small drop in CAML:Central Asia Metals. OPTI:Optibiotix is mostly responsible for the drop in value. Long term average monthly profits are very similar to the other account, dropping by around £3 a week with no sales. The 6.8% buffer I have over my target income of 10% means I'm under no pressure to sell for a long time.

The drop was enough to take the portfolio back into the red, but only just.

The trading portfolio looks like this after 88 dismal weeks

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£161.74	(-53.2%)	-£14.78
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£26.30	(-91.3%)	+£0.75
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£11.83	(-41.1%)	+£0.13
(Sold stocks profit + Dividends - Fees / Months)

The last few weeks this has bounced up and down by £14, but it needs to bounce up a hell of a lot further before I can get rid and start using this account properly.

Yuck!

I've not reviewed Nemesis Share contenders for a while. Clearly OPTI:Optibiotix is winning hands down with losses of £6,993, but who's next? For a long time my contenders were losing around £800 but it's worse than that now.

In second place is JLP:Jubilee Metals which has dived from almost being in profit to £1,985 paper loss thanks to shareholders losing trust in the directors. There's still a great deal of promise here, but even loyal long term holders are feeling pretty fed up at the moment.

In third place is TRX:Tissue Regenix which is losing £1,107 in my SIPP as I kept buying at around 18.5p, convinced it had a great global future. The problem is the cash burn is far greater than the revenue coming in, and there's no sign of that changing, so this is going to have to be a long term holding with the hope that a big company will buy them out and teach them how to make a profit.

Apart from BLOC:Block Commodities (ex AFPO:African Potash) which appears to be just a bandwagon-following mechanism for directors to earn a living using shareholders cash, and is losing £714, everything else is losing between £100 and £500 so nothing too serious, just lots and lots of small losses but with reasonable chance of moving to profit for quite a few of them.

So although a certain amount of doom and gloom with the current portfolio value, I'm optimistic things will get better as news filters through over the next few months.